New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
Cedars-Sinai Cancer physician-scientists and thought leaders will discuss scientific advances, new therapies, and the future of cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4 in Chicago.
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
A study led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.
ASCO: A new study highlights workplace discrimination reported by internationally trained female oncologists. Dr. Coral Olazagasti will present study findings that showed female oncologists reported much higher levels of gender or race/ethnicity-based discrimination than their male counterparts.
ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
AT ASCO: A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors.
Researchers from Penn Medicine’s Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, happening May 31—June 4, 2024 in Chicago and online.
New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.
ASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.
Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
